Drug intelligence / Profile preview

aceclofenac + paracetamol + chlorzoxazone

Development stage
Unknown
Lead developer
Kriam Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Aceclofenac + paracetamol + chlorzoxazone is a fixed-dose combination (FDC) medication developed by Kriam Pharma for the symptomatic treatment of painful muscle spasms associated with musculoskeletal conditions. Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting the cyclooxygenase-2 (COX-2) enzyme, thereby reducing the production of prostaglandins that cause pain and inflammation. Paracetamol acts as an additional analgesic and antipyretic, likely through the inhibition of prostaglandin synthesis in the central nervous system. Chlorzoxazone is a centrally acting skeletal muscle relaxant that inhibits multi-synaptic reflex arcs at the level of the spinal cord and subcortical areas of the brain, leading to muscle relaxation. This oral combination is typically used for conditions such as low back pain, sprains, and strains where both pain and muscle tension are present.

Brand names
KRIAM-MR
Other names
Aceclofenac, Paracetamol, and Chlorzoxazone Tablets
02

Targets

KCNN1 (Small conductance calcium-activated potassium channel protein 1)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on aceclofenac + paracetamol + chlorzoxazone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aceclofenac + paracetamol + chlorzoxazone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call